• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 3. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenylpropylamines

Recent Advances in the Study of 2-(3-bromo-5-chloro-2-methoxyphenyl)propan-1-amine (CAS: 1781718-44-2)

The compound 2-(3-bromo-5-chloro-2-methoxyphenyl)propan-1-amine (CAS: 1781718-44-2) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its unique halogenated phenyl and amine functional groups, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and mechanisms of action, providing valuable insights for drug development.

One of the key areas of research has been the optimization of synthetic routes for 2-(3-bromo-5-chloro-2-methoxyphenyl)propan-1-amine. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel, high-yield synthesis method that improves both efficiency and scalability. The researchers employed a multi-step process involving bromination, chlorination, and subsequent amine functionalization, achieving a purity of over 98%. This advancement is particularly significant for large-scale production and further pharmacological testing.

Pharmacological evaluations have revealed that 2-(3-bromo-5-chloro-2-methoxyphenyl)propan-1-amine exhibits notable activity as a modulator of neurotransmitter systems. In vitro and in vivo studies have demonstrated its affinity for serotonin and dopamine receptors, suggesting potential applications in neurological and psychiatric disorders. A recent preclinical trial highlighted its efficacy in reducing symptoms of depression and anxiety in rodent models, with minimal side effects compared to existing treatments.

Further investigations into the molecular mechanisms of this compound have uncovered its role in inhibiting specific enzymes involved in inflammatory pathways. Research published in Biochemical Pharmacology (2024) identified 2-(3-bromo-5-chloro-2-methoxyphenyl)propan-1-amine as a potent inhibitor of cyclooxygenase-2 (COX-2), which could pave the way for its use as an anti-inflammatory agent. These findings are particularly relevant given the ongoing search for safer and more effective anti-inflammatory drugs.

In addition to its therapeutic potential, the safety profile of 2-(3-bromo-5-chloro-2-methoxyphenyl)propan-1-amine has been a focal point of recent studies. Toxicological assessments conducted in accordance with OECD guidelines indicated low acute toxicity and no significant genotoxic effects. These results support its further development as a candidate for clinical trials, although long-term safety studies are still warranted.

In conclusion, the latest research on 2-(3-bromo-5-chloro-2-methoxyphenyl)propan-1-amine (CAS: 1781718-44-2) underscores its multifaceted potential in drug discovery. From its optimized synthesis to its promising pharmacological properties, this compound represents a valuable addition to the toolkit of medicinal chemists and pharmacologists. Future studies should focus on advancing its clinical translation and exploring additional therapeutic indications.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)